NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsMinimalNeutral
Announced Thu, 9 Apr · 16:29 IST

Neuland Laboratories Limited has informed the Exchange regarding 'Compliance Certificate Pursuant To SEBI Exemption Order Dated January 3, 2025 For The Financial Year Ended March 31, 2026'.

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-1.5%1-day move
₹14720.00
prior close
₹14723.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6-0.2+1.4+2.4-1.5+2.2+2.0+3.7+2.9+2.2+10.0+19.6+14.9+32.4
Up moveDown movePending
AI summary

Davuluri Ownership Trust (a promoter-linked entity of Neuland Laboratories) has filed an annual compliance certificate with BSE, NSE, and SEBI for FY ended March 31, 2026. This filing is required under a SEBI Exemption Order dated January 3, 2025, read with Regulation 11 of the SEBI Takeover Code (SAST Regulations, 2011). The Trust was granted an exemption from certain takeover code obligations, and an independent auditor (M/s. B Srinivasa Rao & Co.) has verified and certified that the Trust has complied with all stipulated conditions during the year. The certificate was signed by auditor Ranga Rao Ch on April 7, 2026, and submitted to exchanges on April 9, 2026.

Likely market impact

This is a routine regulatory compliance filing by a promoter-group trust and has no direct impact on the company's operations, financials, or share price. It simply confirms that the promoter entity continues to meet the conditions attached to its SEBI exemption from takeover code provisions. Shareholders need not take any action.